222 related articles for article (PubMed ID: 23919839)
1. An economic evaluation for prevention of diabetes mellitus in a developing country: a modelling study.
Liu X; Li C; Gong H; Cui Z; Fan L; Yu W; Zhang C; Ma J
BMC Public Health; 2013 Aug; 13():729. PubMed ID: 23919839
[TBL] [Abstract][Full Text] [Related]
2. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom.
Palmer AJ; Roze S; Valentine WJ; Spinas GA; Shaw JE; Zimmet PZ
Clin Ther; 2004 Feb; 26(2):304-21. PubMed ID: 15038953
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
[TBL] [Abstract][Full Text] [Related]
4. Screening for type 2 diabetes: literature review and economic modelling.
Waugh N; Scotland G; McNamee P; Gillett M; Brennan A; Goyder E; Williams R; John A
Health Technol Assess; 2007 May; 11(17):iii-iv, ix-xi, 1-125. PubMed ID: 17462167
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
Eddy DM; Schlessinger L; Kahn R
Ann Intern Med; 2005 Aug; 143(4):251-64. PubMed ID: 16103469
[TBL] [Abstract][Full Text] [Related]
6. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
Palmer AJ; Tucker DM
Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of a Short Message Service Intervention to Prevent Type 2 Diabetes from Impaired Glucose Tolerance.
Wong CK; Jiao FF; Siu SC; Fung CS; Fong DY; Wong KW; Yu EY; Lo YY; Lam CL
J Diabetes Res; 2016; 2016():1219581. PubMed ID: 26798647
[TBL] [Abstract][Full Text] [Related]
8. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
Flórez H
Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
Caro JJ; Getsios D; Caro I; Klittich WS; O'Brien JA
Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
Avenell A; Broom J; Brown TJ; Poobalan A; Aucott L; Stearns SC; Smith WC; Jung RT; Campbell MK; Grant AM
Health Technol Assess; 2004 May; 8(21):iii-iv, 1-182. PubMed ID: 15147610
[TBL] [Abstract][Full Text] [Related]
11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
12. Summaries for patients. The cost-effectiveness of strategies to prevent type 2 diabetes.
Ann Intern Med; 2005 Mar; 142(5):I28. PubMed ID: 15738446
[No Abstract] [Full Text] [Related]
13. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care.
Bertram MY; Lim SS; Barendregt JJ; Vos T
Diabetologia; 2010 May; 53(5):875-81. PubMed ID: 20135088
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of type 2 diabetes prevention programmes: Markov model of low- and high-intensity lifestyle programmes and metformin in participants with different categories of intermediate hyperglycaemia.
Roberts S; Craig D; Adler A; McPherson K; Greenhalgh T
BMC Med; 2018 Jan; 16(1):16. PubMed ID: 29378576
[TBL] [Abstract][Full Text] [Related]
15. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis.
Gillies CL; Lambert PC; Abrams KR; Sutton AJ; Cooper NJ; Hsu RT; Davies MJ; Khunti K
BMJ; 2008 May; 336(7654):1180-5. PubMed ID: 18426840
[TBL] [Abstract][Full Text] [Related]
16. The economics of diabetes prevention.
Herman WH
Med Clin North Am; 2011 Mar; 95(2):373-84, viii. PubMed ID: 21281839
[TBL] [Abstract][Full Text] [Related]
17. Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation.
Thomas C; Sadler S; Breeze P; Squires H; Gillett M; Brennan A
BMJ Open; 2017 Aug; 7(8):e014953. PubMed ID: 28827235
[TBL] [Abstract][Full Text] [Related]
18. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design.
Sun X; Guo L; Shang H; Ren M; Wang Y; Huo D; Lei X; Wang H; Zhai J
Trials; 2015 Nov; 16():496. PubMed ID: 26530718
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of a lifestyle intervention in high-risk individuals for diabetes in a low- and middle-income setting: Trial-based analysis of the Kerala Diabetes Prevention Program.
Sathish T; Oldenburg B; Thankappan KR; Absetz P; Shaw JE; Tapp RJ; Zimmet PZ; Balachandran S; Shetty SS; Aziz Z; Mahal A
BMC Med; 2020 Sep; 18(1):251. PubMed ID: 32883279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
